Relmada Therapeutics ( (RLMD) ) has shared an update.
Relmada Therapeutics Inc (RLMD) stock saw a decline, ending the day at $0.45 which represents a decrease of $-0.07 or -13.46% from the prior close of $0.52. The stock opened at $0.52 and touched a low ...
Mizuho has recently reduced Relmada Therapeutics Inc (RLMD) stock to Neutral rating, as announced on December 5, 2024, according to Finviz. Earlier, on September 17, 2024, Jefferies had raised the ...
In a recent transaction, Charles J. Casamento, a director at Relmada Therapeutics , Inc. (NASDAQ:RLMD), purchased shares of the company's common stock. The transaction, which took... Paul Edward ...
Inverted Hammer 15 68 Dec 23, 2024 14:30 ...
Relmada Therapeutics (NASDAQ:RLMD) has announced its financial results for the fourth quarter and full year of 2023, focusing on the advancement of its Phase 3 program for ...
Investing.com – U.S. equities were higher at the close on Monday, as gains in the Oil & Gas, Financials and Technology sectors propelled shares higher. At the close in NYSE, the... Investing.com – U.S ...
Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases.
Investing.com - Relmada Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations. Relmada Therapeutics ...
In a recent transaction, Charles J. Casamento, a director at Relmada Therapeutics , Inc. (NASDAQ:RLMD), purchased shares of the company's common stock. The transaction, which... NEW YORK, Sept. 05, ...
AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...